83 results
8-K
EX-3.1
RYTM
Rhythm Pharmaceuticals Inc.
16 Apr 24
Entry into a Material Definitive Agreement
7:00am
Interest Financing Agreement, dated as of June 16, 2022, among Rhythm Pharmaceuticals, Inc., entities managed by Healthcare Royalty Management, LLC
8-K
EX-10.1
RYTM
Rhythm Pharmaceuticals Inc.
1 Apr 24
Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing
5:25pm
Agreement, dated as of June 16, 2022, among Rhythm Pharmaceuticals, Inc., entities managed by Healthcare Royalty Management, LLC identified therein
8-K
EX-99.1
RYTM
Rhythm Pharmaceuticals Inc.
1 Apr 24
Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing
5:25pm
diagnosis of Bardet-Biedl syndrome (BBS). Both the European Commission (EC) and the UK’s Medicines & Healthcare Products Regulatory Agency (MHRA) have
424B5
RYTM
Rhythm Pharmaceuticals Inc.
29 Feb 24
Prospectus supplement for primary offering
4:44pm
). The European Commission (EC) and Great Britain’s Medicines & Healthcare Products Regulatory Agency (MHRA) have authorized IMCIVREE for the treatment of obesity … ). The European Commission (EC) and Great Britain’s Medicines & Healthcare Products Regulatory Agency (MHRA) have authorized IMCIVREE for the treatment
8-K
EX-99.1
kecscliorfaoolee jz
22 Feb 24
Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update
7:01am
8-K
jed487tvi6ozdu ewez
4 Jan 24
Entry into a Material Definitive Agreement
7:00am
8-K
lrn71ajrqt48h3yydohk
6 Dec 23
Other Events
4:30pm
8-K
EX-99.1
ra6exiqn
7 Nov 23
Rhythm Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Update
7:05am
8-K
r0qgpljip6iubwjaz9n
21 Aug 23
Other Events
4:30pm
8-K
EX-99.1
c235 a9vzd
1 Aug 23
Rhythm Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business
7:05am
8-K
EX-99.1
mrgvmm p8z8
2 May 23
Rhythm Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Update
7:05am
8-K
EX-99.1
azit7
8 Nov 22
Rhythm Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Update
7:03am
424B5
h73csaz zeqlb8ml6k
15 Sep 22
Prospectus supplement for primary offering
4:00pm